Zydus Lifesciences has informed that it enclosed a copy of press release dated July 22, 2024 titled ‘Zydus receives approval from COFEPRIS of Mexico to market Bhava™ (Bevacizumab biosimilar) to treat various cancers’.
The above information is a part of company’s filings submitted to BSE.